139 related articles for article (PubMed ID: 35230518)
1. Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection.
Lüdemann W; Kahn J; Pustelnik D; Hardt J; Böning G; Jonczyk M; Amthauer H; Gebauer B; Hamm B; Wieners G
Eur Radiol; 2022 Jul; 32(7):4687-4698. PubMed ID: 35230518
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Imaging Biomarkers for
Schobert I; Chapiro J; Nezami N; Hamm CA; Gebauer B; Lin M; Pollak J; Saperstein L; Schlachter T; Savic LJ
J Nucl Med; 2019 Aug; 60(8):1066-1072. PubMed ID: 30655331
[TBL] [Abstract][Full Text] [Related]
3.
Jreige M; Mitsakis P; Van Der Gucht A; Pomoni A; Silva-Monteiro M; Gnesin S; Boubaker A; Nicod-Lalonde M; Duran R; Prior JO; Denys A; Schaefer N
Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1215-1222. PubMed ID: 28233086
[TBL] [Abstract][Full Text] [Related]
4. A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study.
Kokabi N; Galt JR; Xing M; Camacho JC; Barron BJ; Schuster DM; Kim HS
J Vasc Interv Radiol; 2014 Feb; 25(2):277-87. PubMed ID: 24461133
[TBL] [
